Maternal Serum S100-B, PAPP-A and IL-6 levels in severe preeclampsia

Artunc-Ulkumen B.; Guvenc Y.; Goker A.; Gozukara C.

Maternal Serum S100-B, PAPP-A and IL-6 levels in severe preeclampsia

Date

2015

Authors

Publisher

Springer Verlag

Abstract

Aim: We aimed to investigate the relationship of maternal serum levels of S100-B, PAPP-A and IL-6 with severe preeclampsia. Materials and methods: This prospective case–control study consisted of 27 severe preeclamptic and 36 healthy singleton pregnancies. The groups were matched for parity, maternal age and body mass index. Maternal blood sampling for S100B, PAPP-A and IL-6 was performed at the morning after an overnight fasting. Results: S100-B concentrations were significantly higher in severe preeclampsia group (0.09 ± 0.05 vs. 0.13 ± 0.01 µg/L; p = 0.025). PAPP-A levels were higher (196.54 ± 21.56 vs. 208.80 ± 23.97 mIU/ml; p = 0.707) and IL-6 levels were lower in severe preeclamptic group (68.79 ± 29.89 vs. 37.30 ± 6.46 pg/ml; p = 0.372). AUC value for S100-B was calculated as 0.712. When cutoff level for serum S100-B for predicting severe preeclampsia was regarded as 0.0975 µg/L, sensitivity and specificity were found to be 81.4 % and 58.3 %, respectively. Pregnancies with ≥0.0975 µg/L S100-B levels had 12.75-fold increased risk for having CNS symptoms (OR 12.75; 95 % CI 2.69–60.28) and 3.27-fold increased risk for having HELLP syndrome (OR 3.27; 95 % CI 0.62–17.36). Conclusion: Our results suggest that serum S100B levels may be a potential marker in severe preeclampsia for the severity of hypoperfusion both in placenta and brain pointing at subsequent risk of organ failure. © 2015, Springer-Verlag Berlin Heidelberg.